Our History

bioMérieux is a family-owned company created in 1963. Its expertise and its commitment to expand the frontiers of knowledge in biology are grounded in an entrepreneurial adventure that has been ongoing for more than one century.

bioMérieux is first and foremost a human and scientific adventure that began more than 55 years ago, yet its roots reach back to the tradition of Louis Pasteur and the fight against infectious diseases. In 1897, Marcel Mérieux, who had studied with Pasteur, founded a laboratory in Lyon where he developed the first anti-tetanus sera. 

He called it Institut Mérieux, and from the outset began to lay the groundwork for a bio-industrial edifice that would leave its mark on vaccinology and the diagnosis of infectious diseases worldwide. Under the direction of his son, Dr. Charles Mérieux, and later his grandson, Alain Mérieux, Institut Mérieux grew to become world leader in human and veterinary vaccines. The Institute gave rise to companies that rank today as major players in public health, such as Sanofi Pasteur and Merial.

In 1994, Alain Mérieux shifted his focus from the vaccines activity to concentrate on the family holding and its diagnostics and immunotherapy businesses, including bioMérieux.

In 2014, Alexandre Mérieux, Marcel’s great-grandson, took up the torch and today continues the family tradition as CEO of bioMérieux. Then he was appointed Chairman and CEO by the Board of Directors in December 2017.

As part of the 16th edition of the BFM AWARDS, held under the theme of resilience in this special year, Alexandre Mérieux received, on behalf of bioMérieux and all its employees, the Family Saga Award on November 30, 2020. 

Photo credit: David Nivière

This ceremony rewards, in 6 categories, daring entrepreneurs who, despite the context of the pandemic, have managed to seize opportunities while controlling the risk for their employees and customers.

On the occasion of the award presentation by Margueritte Bérard, Director of Networks France at BNP Paribas, and the French Chef Hélène Darroze, Alexandre Mérieux, bioMérieux CEO, spoke about the company's historic public health mission, its long-term innovation strategy and the importance of diagnostics against COVID-19 and beyond, to fight against infectious diseases.